Newsmeme!
Discover News you didn't know existed
A team led by Craig Pikaard, Ph.D., Washington University in St. Louis professor of biology in Arts & Sciences, has made a breakthrough in understanding the phenomenon of nucleolar dominance, the silencing of an entire parental set of ribosomal RNA genes in a hybrid plant or animal.
A team led by Craig Pikaard, Ph.D., WUSTL professor of biology in Arts & Sciences, has made a breakthrough in understanding the phenomenon of nucleolar dominance, the silencing of an entire parental set of ribosomal RNA genes in a hybrid plant or animal.
( Washington University in St. Louis ) A team led by Craig Pikaard, Ph.D., WUSTL professor of biology in arts and sciences, has made a breakthrough in understanding the phenomenon of nucleolar dominance, the silencing of an entire parental set of ribosomal RNA genes in a hybrid plant or animal. Since the machinery involved in nucleolar dominance is some of the same machinery that can go haywire ...
Researchers at Columbia University Medical Center and the State University of New York at Stony Brook (SUNY) have developed a groundbreaking technique to sneak therapeutic genes past the body's defenses, possibly clearing one of the largest hurdles to realizing the potentials of medically altering a patient's DNA.
NORWOOD, Mass.----Boston Biomedical, Inc.:
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has been selected as a 2009 Technology Pioneer by the World Economic Forum. Each year, the World Economic Forum awards companies from a variety of fields who have demonstrated visionary leadership and are involved in the development of a life-changing technology.
MIAMI----OPKO Health, Inc. announced today that it has completed enrollment in the Company’s Phase III clinical trial of bevasiranib for the treatment of wet age-related macular degeneration .
CAMBRIDGE, Mass.----Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, announced today that it has been selected as a 2009 Technology Pioneer by the World Economic Forum.
Intradigm, a developer of targeted, systemic RNA interference therapeutics, has received a new US patent that claims methods of enhancing the RNA silencing activity of an RNAi agent through certain structural modifications in various cell types, including mammalian.
AiRNA Pharmaceuticals, Inc., a RNAi therapeutics company based on next generation proprietary RNAi technologies, and Boston Biomedical, Inc., a biotechnology company developing novel therapies targeting cancer stem cells, today announced that asymmetrical interfering RNA (aiRNA), a new fundamental RNAi technology discovered by the companies, is being published in the December issue of Nature ...
Related News Resources:
> HGH News
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |